Can a shorter bladder cancer treatment time cut side effects?

NCT ID NCT04701151

Ongoing Symptom relief Sponsor: Jørgen Bjerggaard Jensen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether reducing the time BCG stays in the bladder (dwell-time) can lessen severe side effects in people with high-risk non-muscle invasive bladder cancer. About 314 patients from Nordic countries will either get the standard dwell-time or a shorter one based on their side effect severity. The goal is to help more patients complete their full treatment plan and lower the chance of cancer coming back.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Bacillus Calmette Guerin (BCG)
What this could lead to: If it works, this could offer a way to manage severe side effects from BCG therapy, helping more patients finish their full treatment course and potentially reduce cancer recurrence.
What could go wrong: This is a phase 4 study focused on side effects, not on proving the treatment works better. Reducing dwell-time might not ease side effects for everyone, and it could still affect how well the BCG fights the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-MUSCLE INVASIVE BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-invasive bladder urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SIDE EFFECT OF DRUG

Contacts and locations

Locations

Aarhus University Hospital

Aarhus, Aarhus N, 8200, Denmark
Department of Urology, Aalborg University Hospital

Aalborg, 9100, Denmark
Department of Urology, Rigshospitalet

Copenhagen, 2100, Denmark
Herlev Hospital

Herlev, Denmark
Karolinska University Hospital

Stockholm, 141-86, Sweden
Landspitali University Hospital

Reykjavik, 101, Iceland
Odense University Hospital

Odense, 5000, Denmark
PO Sahlgrenska Universitetssjukhuset

Gothenburg, sw 413 45, Sweden
Regional Hospital Gødstrup

Herning, 7400, Denmark
Zealand University Hospital

Roskilde, 4000, Denmark
Örebro University Hospital

Örebro, 701 85, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.